nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—hematologic cancer	0.391	1	CpDpCtD
Dihydroergotamine—ABCB1—hematologic cancer	0.0879	1	CbGaD
Dihydroergotamine—ABCB1—Lenalidomide—hematologic cancer	0.0209	0.0698	CbGbCtD
Dihydroergotamine—CYP3A4—Bexarotene—hematologic cancer	0.0125	0.0418	CbGbCtD
Dihydroergotamine—ABCB1—Daunorubicin—hematologic cancer	0.0122	0.0409	CbGbCtD
Dihydroergotamine—ABCB1—Alitretinoin—hematologic cancer	0.012	0.0401	CbGbCtD
Dihydroergotamine—CYP3A4—Lomustine—hematologic cancer	0.0116	0.0389	CbGbCtD
Dihydroergotamine—CYP3A4—Busulfan—hematologic cancer	0.0116	0.0389	CbGbCtD
Dihydroergotamine—CYP3A4—Thiotepa—hematologic cancer	0.0104	0.0347	CbGbCtD
Dihydroergotamine—ABCB1—Imatinib—hematologic cancer	0.00937	0.0313	CbGbCtD
Dihydroergotamine—ABCB1—Nilotinib—hematologic cancer	0.00852	0.0285	CbGbCtD
Dihydroergotamine—ABCB1—Vinorelbine—hematologic cancer	0.00844	0.0282	CbGbCtD
Dihydroergotamine—CYP3A4—Methoxsalen—hematologic cancer	0.00806	0.027	CbGbCtD
Dihydroergotamine—CYP3A4—Bortezomib—hematologic cancer	0.00766	0.0256	CbGbCtD
Dihydroergotamine—ABCB1—Dasatinib—hematologic cancer	0.00753	0.0252	CbGbCtD
Dihydroergotamine—ABCB1—Mitoxantrone—hematologic cancer	0.00743	0.0249	CbGbCtD
Dihydroergotamine—CYP3A4—Daunorubicin—hematologic cancer	0.00733	0.0245	CbGbCtD
Dihydroergotamine—ABCB1—Betamethasone—hematologic cancer	0.00663	0.0222	CbGbCtD
Dihydroergotamine—ABCB1—Gemcitabine—hematologic cancer	0.00657	0.022	CbGbCtD
Dihydroergotamine—ABCB1—Prednisolone—hematologic cancer	0.00654	0.0219	CbGbCtD
Dihydroergotamine—CYP3A4—Cytarabine—hematologic cancer	0.00647	0.0216	CbGbCtD
Dihydroergotamine—CYP3A4—Teniposide—hematologic cancer	0.00637	0.0213	CbGbCtD
Dihydroergotamine—ABCB1—Prednisone—hematologic cancer	0.00617	0.0207	CbGbCtD
Dihydroergotamine—CYP3A4—Ifosfamide—hematologic cancer	0.00588	0.0197	CbGbCtD
Dihydroergotamine—ABCB1—Irinotecan—hematologic cancer	0.00585	0.0196	CbGbCtD
Dihydroergotamine—CYP3A4—Imatinib—hematologic cancer	0.00561	0.0188	CbGbCtD
Dihydroergotamine—CYP3A4—Ruxolitinib—hematologic cancer	0.00529	0.0177	CbGbCtD
Dihydroergotamine—ABCB1—Vinblastine—hematologic cancer	0.0052	0.0174	CbGbCtD
Dihydroergotamine—ABCB1—Vincristine—hematologic cancer	0.00512	0.0171	CbGbCtD
Dihydroergotamine—CYP3A4—Nilotinib—hematologic cancer	0.0051	0.0171	CbGbCtD
Dihydroergotamine—CYP3A4—Vinorelbine—hematologic cancer	0.00506	0.0169	CbGbCtD
Dihydroergotamine—ABCB1—Cisplatin—hematologic cancer	0.00477	0.016	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—hematologic cancer	0.00469	0.0157	CbGbCtD
Dihydroergotamine—CYP3A4—Triamcinolone—hematologic cancer	0.00463	0.0155	CbGbCtD
Dihydroergotamine—CYP3A4—Dasatinib—hematologic cancer	0.00451	0.0151	CbGbCtD
Dihydroergotamine—CYP3A4—Mitoxantrone—hematologic cancer	0.00445	0.0149	CbGbCtD
Dihydroergotamine—CYP3A4—Betamethasone—hematologic cancer	0.00397	0.0133	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisolone—hematologic cancer	0.00392	0.0131	CbGbCtD
Dihydroergotamine—ABCB1—Dexamethasone—hematologic cancer	0.00385	0.0129	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisone—hematologic cancer	0.0037	0.0124	CbGbCtD
Dihydroergotamine—CYP3A4—Irinotecan—hematologic cancer	0.00351	0.0117	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—hematologic cancer	0.0032	0.0107	CbGbCtD
Dihydroergotamine—CYP3A4—Vinblastine—hematologic cancer	0.00312	0.0104	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—hematologic cancer	0.0031	0.0104	CbGbCtD
Dihydroergotamine—CYP3A4—Vincristine—hematologic cancer	0.00307	0.0103	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—hematologic cancer	0.00281	0.0094	CbGbCtD
Dihydroergotamine—CYP3A4—Dexamethasone—hematologic cancer	0.00231	0.00773	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—hematologic cancer	0.00192	0.00641	CbGbCtD
Dihydroergotamine—Headache—Mitoxantrone—hematologic cancer	3.01e-05	0.000169	CcSEcCtD
Dihydroergotamine—Headache—Irinotecan—hematologic cancer	3.01e-05	0.000169	CcSEcCtD
Dihydroergotamine—Nausea—Ifosfamide—hematologic cancer	3.01e-05	0.000169	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3e-05	0.000169	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3e-05	0.000169	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—hematologic cancer	2.99e-05	0.000168	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—hematologic cancer	2.99e-05	0.000168	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Triamcinolone—hematologic cancer	2.99e-05	0.000168	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—hematologic cancer	2.99e-05	0.000168	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—hematologic cancer	2.98e-05	0.000167	CcSEcCtD
Dihydroergotamine—Vomiting—Gemcitabine—hematologic cancer	2.98e-05	0.000167	CcSEcCtD
Dihydroergotamine—Insomnia—Dexamethasone—hematologic cancer	2.98e-05	0.000167	CcSEcCtD
Dihydroergotamine—Insomnia—Betamethasone—hematologic cancer	2.98e-05	0.000167	CcSEcCtD
Dihydroergotamine—Paraesthesia—Dexamethasone—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Paraesthesia—Betamethasone—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Rash—Gemcitabine—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Dermatitis—Gemcitabine—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—hematologic cancer	2.95e-05	0.000166	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—hematologic cancer	2.94e-05	0.000165	CcSEcCtD
Dihydroergotamine—Headache—Gemcitabine—hematologic cancer	2.93e-05	0.000165	CcSEcCtD
Dihydroergotamine—Nausea—Vincristine—hematologic cancer	2.93e-05	0.000165	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—hematologic cancer	2.93e-05	0.000165	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—hematologic cancer	2.93e-05	0.000165	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisolone—hematologic cancer	2.91e-05	0.000163	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—hematologic cancer	2.9e-05	0.000163	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—hematologic cancer	2.9e-05	0.000163	CcSEcCtD
Dihydroergotamine—Dyspepsia—Betamethasone—hematologic cancer	2.9e-05	0.000163	CcSEcCtD
Dihydroergotamine—Dyspepsia—Dexamethasone—hematologic cancer	2.9e-05	0.000163	CcSEcCtD
Dihydroergotamine—Urticaria—Triamcinolone—hematologic cancer	2.88e-05	0.000162	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—hematologic cancer	2.87e-05	0.000161	CcSEcCtD
Dihydroergotamine—Body temperature increased—Triamcinolone—hematologic cancer	2.87e-05	0.000161	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—hematologic cancer	2.87e-05	0.000161	CcSEcCtD
Dihydroergotamine—Decreased appetite—Dexamethasone—hematologic cancer	2.86e-05	0.000161	CcSEcCtD
Dihydroergotamine—Decreased appetite—Betamethasone—hematologic cancer	2.86e-05	0.000161	CcSEcCtD
Dihydroergotamine—Nausea—Mitoxantrone—hematologic cancer	2.85e-05	0.000161	CcSEcCtD
Dihydroergotamine—Nausea—Irinotecan—hematologic cancer	2.85e-05	0.000161	CcSEcCtD
Dihydroergotamine—Fatigue—Dexamethasone—hematologic cancer	2.84e-05	0.00016	CcSEcCtD
Dihydroergotamine—Fatigue—Betamethasone—hematologic cancer	2.84e-05	0.00016	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—hematologic cancer	2.83e-05	0.000159	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—hematologic cancer	2.83e-05	0.000159	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—hematologic cancer	2.82e-05	0.000159	CcSEcCtD
Dihydroergotamine—Pain—Dexamethasone—hematologic cancer	2.81e-05	0.000158	CcSEcCtD
Dihydroergotamine—Pain—Betamethasone—hematologic cancer	2.81e-05	0.000158	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—hematologic cancer	2.81e-05	0.000158	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—hematologic cancer	2.8e-05	0.000157	CcSEcCtD
Dihydroergotamine—Nausea—Gemcitabine—hematologic cancer	2.78e-05	0.000156	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—hematologic cancer	2.77e-05	0.000156	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—hematologic cancer	2.77e-05	0.000156	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—hematologic cancer	2.75e-05	0.000155	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—hematologic cancer	2.75e-05	0.000155	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—hematologic cancer	2.74e-05	0.000154	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—hematologic cancer	2.73e-05	0.000154	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—hematologic cancer	2.72e-05	0.000153	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—hematologic cancer	2.72e-05	0.000153	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Betamethasone—hematologic cancer	2.71e-05	0.000152	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Dexamethasone—hematologic cancer	2.71e-05	0.000152	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—hematologic cancer	2.71e-05	0.000152	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—hematologic cancer	2.69e-05	0.000152	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.69e-05	0.000151	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.69e-05	0.000151	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Triamcinolone—hematologic cancer	2.67e-05	0.00015	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—hematologic cancer	2.67e-05	0.00015	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—hematologic cancer	2.65e-05	0.000149	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—hematologic cancer	2.64e-05	0.000149	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—hematologic cancer	2.64e-05	0.000148	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—hematologic cancer	2.64e-05	0.000148	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—hematologic cancer	2.62e-05	0.000147	CcSEcCtD
Dihydroergotamine—Urticaria—Dexamethasone—hematologic cancer	2.61e-05	0.000147	CcSEcCtD
Dihydroergotamine—Urticaria—Betamethasone—hematologic cancer	2.61e-05	0.000147	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.61e-05	0.000147	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisolone—hematologic cancer	2.61e-05	0.000147	CcSEcCtD
Dihydroergotamine—Asthenia—Triamcinolone—hematologic cancer	2.6e-05	0.000146	CcSEcCtD
Dihydroergotamine—Abdominal pain—Betamethasone—hematologic cancer	2.6e-05	0.000146	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dexamethasone—hematologic cancer	2.6e-05	0.000146	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dexamethasone—hematologic cancer	2.6e-05	0.000146	CcSEcCtD
Dihydroergotamine—Body temperature increased—Betamethasone—hematologic cancer	2.6e-05	0.000146	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—hematologic cancer	2.59e-05	0.000146	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—hematologic cancer	2.59e-05	0.000146	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—hematologic cancer	2.57e-05	0.000145	CcSEcCtD
Dihydroergotamine—Pruritus—Triamcinolone—hematologic cancer	2.57e-05	0.000144	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—hematologic cancer	2.55e-05	0.000143	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—hematologic cancer	2.54e-05	0.000143	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—hematologic cancer	2.52e-05	0.000142	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—hematologic cancer	2.52e-05	0.000142	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—hematologic cancer	2.52e-05	0.000142	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—hematologic cancer	2.52e-05	0.000142	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—hematologic cancer	2.5e-05	0.000141	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—hematologic cancer	2.5e-05	0.00014	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—hematologic cancer	2.5e-05	0.00014	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—hematologic cancer	2.49e-05	0.00014	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—hematologic cancer	2.49e-05	0.00014	CcSEcCtD
Dihydroergotamine—Rash—Prednisolone—hematologic cancer	2.49e-05	0.00014	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisolone—hematologic cancer	2.48e-05	0.00014	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—hematologic cancer	2.48e-05	0.000139	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—hematologic cancer	2.47e-05	0.000139	CcSEcCtD
Dihydroergotamine—Headache—Prednisolone—hematologic cancer	2.47e-05	0.000139	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—hematologic cancer	2.47e-05	0.000139	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—hematologic cancer	2.47e-05	0.000139	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—hematologic cancer	2.47e-05	0.000139	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—hematologic cancer	2.44e-05	0.000137	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—hematologic cancer	2.43e-05	0.000136	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—hematologic cancer	2.41e-05	0.000136	CcSEcCtD
Dihydroergotamine—Dizziness—Triamcinolone—hematologic cancer	2.4e-05	0.000135	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—hematologic cancer	2.37e-05	0.000134	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—hematologic cancer	2.37e-05	0.000133	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—hematologic cancer	2.36e-05	0.000133	CcSEcCtD
Dihydroergotamine—Asthenia—Dexamethasone—hematologic cancer	2.36e-05	0.000133	CcSEcCtD
Dihydroergotamine—Asthenia—Betamethasone—hematologic cancer	2.36e-05	0.000133	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.36e-05	0.000133	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—hematologic cancer	2.34e-05	0.000132	CcSEcCtD
Dihydroergotamine—Nausea—Prednisolone—hematologic cancer	2.34e-05	0.000132	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—hematologic cancer	2.34e-05	0.000131	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—hematologic cancer	2.34e-05	0.000131	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—hematologic cancer	2.33e-05	0.000131	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—hematologic cancer	2.33e-05	0.000131	CcSEcCtD
Dihydroergotamine—Pruritus—Dexamethasone—hematologic cancer	2.33e-05	0.000131	CcSEcCtD
Dihydroergotamine—Pruritus—Betamethasone—hematologic cancer	2.33e-05	0.000131	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—hematologic cancer	2.31e-05	0.00013	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—hematologic cancer	2.31e-05	0.00013	CcSEcCtD
Dihydroergotamine—Vomiting—Triamcinolone—hematologic cancer	2.31e-05	0.00013	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—hematologic cancer	2.29e-05	0.000129	CcSEcCtD
Dihydroergotamine—Rash—Triamcinolone—hematologic cancer	2.29e-05	0.000129	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—hematologic cancer	2.29e-05	0.000129	CcSEcCtD
Dihydroergotamine—Dermatitis—Triamcinolone—hematologic cancer	2.28e-05	0.000128	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—hematologic cancer	2.28e-05	0.000128	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—hematologic cancer	2.28e-05	0.000128	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—hematologic cancer	2.28e-05	0.000128	CcSEcCtD
Dihydroergotamine—Headache—Triamcinolone—hematologic cancer	2.27e-05	0.000128	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—hematologic cancer	2.27e-05	0.000127	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—hematologic cancer	2.27e-05	0.000127	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—hematologic cancer	2.26e-05	0.000127	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dexamethasone—hematologic cancer	2.25e-05	0.000127	CcSEcCtD
Dihydroergotamine—Diarrhoea—Betamethasone—hematologic cancer	2.25e-05	0.000127	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—hematologic cancer	2.25e-05	0.000126	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—hematologic cancer	2.24e-05	0.000126	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—hematologic cancer	2.24e-05	0.000126	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—hematologic cancer	2.2e-05	0.000124	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—hematologic cancer	2.19e-05	0.000123	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—hematologic cancer	2.19e-05	0.000123	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.18e-05	0.000123	CcSEcCtD
Dihydroergotamine—Dizziness—Dexamethasone—hematologic cancer	2.18e-05	0.000122	CcSEcCtD
Dihydroergotamine—Dizziness—Betamethasone—hematologic cancer	2.18e-05	0.000122	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—hematologic cancer	2.17e-05	0.000122	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—hematologic cancer	2.17e-05	0.000122	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—hematologic cancer	2.16e-05	0.000122	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—hematologic cancer	2.16e-05	0.000122	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—hematologic cancer	2.16e-05	0.000121	CcSEcCtD
Dihydroergotamine—Nausea—Triamcinolone—hematologic cancer	2.15e-05	0.000121	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—hematologic cancer	2.15e-05	0.000121	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—hematologic cancer	2.14e-05	0.00012	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—hematologic cancer	2.14e-05	0.00012	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—hematologic cancer	2.13e-05	0.00012	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—hematologic cancer	2.13e-05	0.00012	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—hematologic cancer	2.12e-05	0.000119	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—hematologic cancer	2.11e-05	0.000119	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—hematologic cancer	2.11e-05	0.000119	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—hematologic cancer	2.09e-05	0.000118	CcSEcCtD
Dihydroergotamine—Vomiting—Dexamethasone—hematologic cancer	2.09e-05	0.000118	CcSEcCtD
Dihydroergotamine—Vomiting—Betamethasone—hematologic cancer	2.09e-05	0.000118	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—hematologic cancer	2.09e-05	0.000118	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—hematologic cancer	2.08e-05	0.000117	CcSEcCtD
Dihydroergotamine—Rash—Dexamethasone—hematologic cancer	2.07e-05	0.000117	CcSEcCtD
Dihydroergotamine—Rash—Betamethasone—hematologic cancer	2.07e-05	0.000117	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—hematologic cancer	2.07e-05	0.000117	CcSEcCtD
Dihydroergotamine—Dermatitis—Betamethasone—hematologic cancer	2.07e-05	0.000117	CcSEcCtD
Dihydroergotamine—Dermatitis—Dexamethasone—hematologic cancer	2.07e-05	0.000117	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—hematologic cancer	2.06e-05	0.000116	CcSEcCtD
Dihydroergotamine—Headache—Betamethasone—hematologic cancer	2.06e-05	0.000116	CcSEcCtD
Dihydroergotamine—Headache—Dexamethasone—hematologic cancer	2.06e-05	0.000116	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—hematologic cancer	2.06e-05	0.000116	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—hematologic cancer	2.05e-05	0.000115	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.04e-05	0.000115	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—hematologic cancer	2.04e-05	0.000115	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—hematologic cancer	2.03e-05	0.000114	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—hematologic cancer	2.03e-05	0.000114	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—hematologic cancer	2.02e-05	0.000114	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—hematologic cancer	2.01e-05	0.000113	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—hematologic cancer	2e-05	0.000113	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—hematologic cancer	2e-05	0.000112	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—hematologic cancer	1.99e-05	0.000112	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—hematologic cancer	1.98e-05	0.000111	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—hematologic cancer	1.97e-05	0.000111	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—hematologic cancer	1.97e-05	0.000111	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—hematologic cancer	1.96e-05	0.00011	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.96e-05	0.00011	CcSEcCtD
Dihydroergotamine—Nausea—Betamethasone—hematologic cancer	1.95e-05	0.00011	CcSEcCtD
Dihydroergotamine—Nausea—Dexamethasone—hematologic cancer	1.95e-05	0.00011	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—hematologic cancer	1.95e-05	0.00011	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—hematologic cancer	1.94e-05	0.000109	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—hematologic cancer	1.93e-05	0.000109	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—hematologic cancer	1.92e-05	0.000108	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—hematologic cancer	1.9e-05	0.000107	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—hematologic cancer	1.89e-05	0.000107	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—hematologic cancer	1.89e-05	0.000106	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—hematologic cancer	1.89e-05	0.000106	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.89e-05	0.000106	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—hematologic cancer	1.88e-05	0.000105	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—hematologic cancer	1.86e-05	0.000105	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—hematologic cancer	1.85e-05	0.000104	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—hematologic cancer	1.85e-05	0.000104	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—hematologic cancer	1.84e-05	0.000104	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.83e-05	0.000103	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—hematologic cancer	1.83e-05	0.000103	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—hematologic cancer	1.82e-05	0.000102	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—hematologic cancer	1.81e-05	0.000102	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—hematologic cancer	1.8e-05	0.000101	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—hematologic cancer	1.8e-05	0.000101	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—hematologic cancer	1.8e-05	0.000101	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—hematologic cancer	1.79e-05	0.000101	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—hematologic cancer	1.78e-05	0.0001	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—hematologic cancer	1.77e-05	9.97e-05	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—hematologic cancer	1.77e-05	9.96e-05	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—hematologic cancer	1.77e-05	9.96e-05	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—hematologic cancer	1.76e-05	9.92e-05	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—hematologic cancer	1.72e-05	9.66e-05	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—hematologic cancer	1.71e-05	9.61e-05	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—hematologic cancer	1.7e-05	9.57e-05	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.7e-05	9.53e-05	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—hematologic cancer	1.69e-05	9.53e-05	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—hematologic cancer	1.65e-05	9.28e-05	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—hematologic cancer	1.65e-05	9.26e-05	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—hematologic cancer	1.64e-05	9.22e-05	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—hematologic cancer	1.64e-05	9.22e-05	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—hematologic cancer	1.64e-05	9.21e-05	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—hematologic cancer	1.61e-05	9.04e-05	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—hematologic cancer	1.59e-05	8.92e-05	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—hematologic cancer	1.58e-05	8.9e-05	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—hematologic cancer	1.53e-05	8.62e-05	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—hematologic cancer	1.53e-05	8.59e-05	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—hematologic cancer	1.52e-05	8.56e-05	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—hematologic cancer	1.51e-05	8.49e-05	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—hematologic cancer	1.51e-05	8.48e-05	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—hematologic cancer	1.5e-05	8.44e-05	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—hematologic cancer	1.49e-05	8.37e-05	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—hematologic cancer	1.48e-05	8.33e-05	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—hematologic cancer	1.47e-05	8.25e-05	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—hematologic cancer	1.42e-05	8.01e-05	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—hematologic cancer	1.42e-05	8e-05	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—hematologic cancer	1.42e-05	7.98e-05	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—hematologic cancer	1.41e-05	7.95e-05	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—hematologic cancer	1.41e-05	7.94e-05	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—hematologic cancer	1.4e-05	7.89e-05	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—hematologic cancer	1.37e-05	7.71e-05	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—hematologic cancer	1.33e-05	7.48e-05	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—hematologic cancer	1.32e-05	7.41e-05	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—hematologic cancer	1.31e-05	7.35e-05	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—hematologic cancer	1.31e-05	7.34e-05	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—hematologic cancer	1.3e-05	7.3e-05	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—hematologic cancer	1.23e-05	6.93e-05	CcSEcCtD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—hematologic cancer	3.36e-06	7.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—hematologic cancer	3.35e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—hematologic cancer	3.35e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—hematologic cancer	3.35e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	3.35e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—hematologic cancer	3.35e-06	7.55e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	3.35e-06	7.55e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NUP98—hematologic cancer	3.35e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—hematologic cancer	3.34e-06	7.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	3.34e-06	7.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—hematologic cancer	3.33e-06	7.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	3.32e-06	7.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	3.32e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	3.31e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—hematologic cancer	3.31e-06	7.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6R—hematologic cancer	3.3e-06	7.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	3.29e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—hematologic cancer	3.29e-06	7.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—hematologic cancer	3.28e-06	7.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JUN—hematologic cancer	3.28e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—hematologic cancer	3.28e-06	7.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—hematologic cancer	3.27e-06	7.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—hematologic cancer	3.26e-06	7.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JUN—hematologic cancer	3.26e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.25e-06	7.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.25e-06	7.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	3.23e-06	7.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NUP214—hematologic cancer	3.23e-06	7.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	3.2e-06	7.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—hematologic cancer	3.2e-06	7.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JUN—hematologic cancer	3.19e-06	7.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—hematologic cancer	3.18e-06	7.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—hematologic cancer	3.18e-06	7.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.16e-06	7.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTR—hematologic cancer	3.16e-06	7.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	3.16e-06	7.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	3.16e-06	7.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—hematologic cancer	3.15e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	3.15e-06	7.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	3.14e-06	7.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—hematologic cancer	3.14e-06	7.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	3.12e-06	7.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	3.11e-06	7.02e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—hematologic cancer	3.11e-06	7.01e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NCOR1—hematologic cancer	3.11e-06	7.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—hematologic cancer	3.11e-06	7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO2—hematologic cancer	3.1e-06	6.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—hematologic cancer	3.1e-06	6.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CREBBP—hematologic cancer	3.09e-06	6.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	3.09e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.09e-06	6.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—hematologic cancer	3.09e-06	6.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—hematologic cancer	3.09e-06	6.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	3.08e-06	6.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—hematologic cancer	3.08e-06	6.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	3.07e-06	6.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—hematologic cancer	3.07e-06	6.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	3.06e-06	6.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	3.04e-06	6.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—hematologic cancer	3.03e-06	6.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	3.02e-06	6.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	3.01e-06	6.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	3.01e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.01e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—hematologic cancer	3.01e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—hematologic cancer	3e-06	6.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JUN—hematologic cancer	3e-06	6.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—hematologic cancer	2.99e-06	6.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	2.95e-06	6.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	2.95e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—hematologic cancer	2.95e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—hematologic cancer	2.94e-06	6.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.94e-06	6.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	2.93e-06	6.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—hematologic cancer	2.92e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	2.92e-06	6.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	2.91e-06	6.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—hematologic cancer	2.9e-06	6.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—hematologic cancer	2.9e-06	6.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	2.88e-06	6.5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	2.88e-06	6.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—hematologic cancer	2.87e-06	6.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JAK2—hematologic cancer	2.86e-06	6.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—hematologic cancer	2.86e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	2.85e-06	6.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	2.85e-06	6.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—hematologic cancer	2.84e-06	6.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	2.84e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRAS—hematologic cancer	2.83e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	2.83e-06	6.38e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—hematologic cancer	2.82e-06	6.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRAS—hematologic cancer	2.81e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	2.81e-06	6.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MDM2—hematologic cancer	2.8e-06	6.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	2.8e-06	6.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	2.79e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	2.79e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	2.79e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	2.79e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	2.77e-06	6.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—hematologic cancer	2.76e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	6.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRAS—hematologic cancer	2.75e-06	6.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.75e-06	6.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	2.74e-06	6.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—hematologic cancer	2.72e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	2.72e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK3—hematologic cancer	2.71e-06	6.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	2.69e-06	6.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—hematologic cancer	2.69e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	2.67e-06	6.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	2.66e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—hematologic cancer	2.64e-06	5.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	2.64e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—hematologic cancer	2.63e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	2.62e-06	5.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—hematologic cancer	2.62e-06	5.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	2.62e-06	5.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	2.61e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	2.6e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	2.6e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—hematologic cancer	2.59e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	2.59e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	2.59e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRAS—hematologic cancer	2.59e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—hematologic cancer	2.56e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	2.56e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	2.56e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	2.55e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	2.53e-06	5.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—hematologic cancer	2.5e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—hematologic cancer	2.5e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.5e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD44—hematologic cancer	2.5e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—hematologic cancer	2.49e-06	5.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	2.48e-06	5.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	2.47e-06	5.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	2.45e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—hematologic cancer	2.44e-06	5.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—hematologic cancer	2.44e-06	5.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JUN—hematologic cancer	2.43e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.43e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—hematologic cancer	2.42e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—hematologic cancer	2.41e-06	5.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	2.4e-06	5.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	2.4e-06	5.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	5.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYCS—hematologic cancer	2.36e-06	5.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	2.36e-06	5.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—hematologic cancer	2.35e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.35e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	2.35e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	2.32e-06	5.22e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.31e-06	5.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	2.3e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	2.29e-06	5.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	2.25e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—hematologic cancer	2.24e-06	5.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	2.24e-06	5.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—hematologic cancer	2.23e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	2.22e-06	5.01e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—hematologic cancer	2.21e-06	4.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.21e-06	4.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	2.2e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.18e-06	4.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	2.18e-06	4.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—hematologic cancer	2.17e-06	4.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.15e-06	4.85e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CREBBP—hematologic cancer	2.14e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.14e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.14e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.12e-06	4.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—hematologic cancer	2.11e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.11e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.1e-06	4.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.1e-06	4.73e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.08e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—hematologic cancer	2.07e-06	4.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.06e-06	4.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.04e-06	4.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.04e-06	4.6e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.03e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	4.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.01e-06	4.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.01e-06	4.52e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—hematologic cancer	2e-06	4.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.98e-06	4.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—hematologic cancer	1.98e-06	4.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—hematologic cancer	1.98e-06	4.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.97e-06	4.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.97e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.97e-06	4.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.96e-06	4.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.95e-06	4.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.95e-06	4.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.95e-06	4.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.93e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.92e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.91e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.91e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.91e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.91e-06	4.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.89e-06	4.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.85e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.85e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.83e-06	4.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.82e-06	4.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.81e-06	4.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.81e-06	4.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	4.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.8e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	4.01e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.77e-06	3.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.76e-06	3.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.71e-06	3.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.69e-06	3.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.67e-06	3.77e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.67e-06	3.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.66e-06	3.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.65e-06	3.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.65e-06	3.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.6e-06	3.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.58e-06	3.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.56e-06	3.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.54e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.53e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.53e-06	3.45e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—hematologic cancer	1.53e-06	3.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.47e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—hematologic cancer	1.46e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.42e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.42e-06	3.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.35e-06	3.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.32e-06	2.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.3e-06	2.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.27e-06	2.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.26e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.25e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—hematologic cancer	1.23e-06	2.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.21e-06	2.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.18e-06	2.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.15e-06	2.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.09e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.08e-06	2.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.06e-06	2.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—hematologic cancer	9.41e-07	2.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—hematologic cancer	8.98e-07	2.02e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—hematologic cancer	8.81e-07	1.99e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.64e-07	1.5e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—hematologic cancer	5.43e-07	1.22e-05	CbGpPWpGaD
